AGIOS PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$413.81 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$413.81M, a 157.64% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $717.97M.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$352.08M.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$231.77M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$413.81M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $717.97M 10-K · filed 2026-02-12 | |
| 2023-12-31 | -$352.08M 10-K · filed 2026-02-12 | |
| 2022-12-31 | -$231.77M 10-K · filed 2025-02-13 | |
| 2021-12-31 | -$356.67M 10-K · filed 2024-02-15 | |
| 2020-12-31 | -$330.67M 10-K · filed 2023-02-23 | -$328.81M 10-K · filed 2021-02-25 |
| 2019-12-31 | -$322.47M 10-K · filed 2022-02-24 | -$432.54M 10-K · filed 2020-02-19 |
| 2018-12-31 | -$311.16M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$290.42M 10-K · filed 2020-02-19 | |
| 2016-12-31 | -$179.90M 10-K · filed 2019-02-14 | |
| 2015-12-31 | -$111.06M 10-K · filed 2018-02-14 | |
| 2014-12-31 | -$53.93M 10-K · filed 2017-02-16 | |
| 2013-12-31 | -$38.83M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |